Answers are grounded in this paper and cite their sources.
L-asparaginase is a chemotherapy drug used to treat acute lymphoblastic leukemia (ALL). The main prerequisite for clinical efficacy of L-asparaginases is micromolar K M for asparagine to allow for complete depletion of this amino acid in the blood. Since currently approved L-asparaginases are of bacterial origin, immunogenicity is a challenge, which would be mitigated by a human enzyme. However, all human L-asparaginases have millimolar K M for asparagine. We recently identified the low K M guinea pig L-asparaginase (gpASNase1). Because gpASNase1 and human L-asparaginase 1 (hASNase1) share ~70% amino-acid identity, we decided to humanize gpASNase1 by generating chimeras with hASNase1 through DNA shuffling. To identify low K M chimeras we developed a suitable bacterial selection system ( E. coli strain BW5Δ). Transforming BW5Δ with the shuffling libraries allowed for the identification of several low K M clones. To further humanize these clones, the C-terminal domain of gpASNase1 was replaced with that of hASNase1. Two of the identified clones, 63 N -h C and 65 N -h C , share respectively 85.7% and 87.1% identity with the hASNase1 but have a K M similar to gpASNase1. These clones possess 100–140 fold enhanced catalytic efficiency compared to hASNase1. Notably, we also show that these highly human-like L-asparaginases maintain their in vitro ALL killing potential.
No takes yet. Share an insight, caveat, or question.
Rigouin et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: